Previous 10 | Next 10 |
home / stock / flhlf / flhlf news
FILAMENT HEALTH CORP. TO LIST ON NASDAQ THROUGH BUSINESS COMBINATION WITH JUPITER ACQUISITION CORPORATION Canada NewsWire Business combination ascribes Filament US$176 million in equity value representing US$0.85 per Filament share and reflects a pro forma enterprise v...
FILAMENT HEALTH ANNOUNCES CHANGE OF AUDITOR Canada NewsWire VANCOUVER, BC , July 14, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development...
FILAMENT HEALTH TO SUPPLY PSILOCYBIN FOR RECIPIENTS OF THE CANADIAN INSTITUTES OF HEALTH RESEARCH PSILOCYBIN OPERATING GRANTS Canada NewsWire The CIHR is funding clinical trials through its Operating Grants for Psilocybin-assisted Psychotherapy for Mental Health and Substance ...
FILAMENT HEALTH ENTERS EXCLUSIVE LICENSING AGREEMENT WITH NEOLUMINA BIOSCIENCE INC. Canada NewsWire NeoLumina's license for Filament's botanical psilocybin drug candidate provides exclusive global right to clinical and commercial development for eating disorders VANC...
FILAMENT HEALTH ANNOUNCES INTERIM RESULTS FROM PHASE I CLINICAL TRIAL AT THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO Canada NewsWire Healthy subjects have been dosed with Filament's botanical psilocybin and psilocin drug candidates VANCOUVER, BC , May 30, ...
2023-05-21 19:30:00 ET Summary Psychedelics being pulled into the mainstream by medical research. Filament Health CEO Benjamin Lightburn on clinical trials, microdosing and real revenue generation. Psilocybin and why of all the psychedelics it probably lends itself best to a r...
FILAMENT HEALTH ANNOUNCES FIRST EVER NAGOYA PROTOCOL-COMPLIANT SHIPMENT OF IBOGA FROM GABON Canada NewsWire The botanical raw material was shipped to Filament's Vancouver facility for analysis and development into ibogaine extract VANCOUVER, BC , May 17, ...
FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire VANCOUVER, BC , May 12, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage n...
FILAMENT HEALTH ANNOUNCES SPRING 2023 EVENT AND MEDIA APPEARANCES Canada NewsWire VANCOUVER, BC , April 25, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug dev...
FILAMENT HEALTH AND PHARMALA BIOTECH ANNOUNCE RELEASE OF GMP MDMA CAPSULES Canada NewsWire Filament subsidiary Psilo Scientific manufactured the drug product on behalf of PharmAla for distribution to clinical trial customers and authorized patients. VANCOUVER, BC ...
News, Short Squeeze, Breakout and More Instantly...
Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Negev Capital Fund One, L.P. (the " Acquiror "), a shareholder of Filament Health Corp. (" Filament "), announces that on June 12, 2024, it was issued 42,284,443 common shares of Filament (the " Common Shares ") from the conversion o...
FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES Canada NewsWire VANCOUVER, BC , June 12, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (" Filament " ...
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER Canada NewsWire Company study investigating PEX010, Filament's botanical psilocybin drug candidate, has been authorized by both FDA and Health Canada...